CHUV

EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

Retrieved on: 
Thursday, February 2, 2023
Cardiovascular disease, CXCR4, Sarcoidosis, Lymphoma, Lausanne University Hospital, Lymphatic system, Muscle tissue, Cardiology, Internal medicine, Diagnosis, Myocarditis, Patient, Leukemia, Research, CHUV, ISS, Nuclear medicine, GMP, Pharmaceutical industry, Medical imaging, Medical device

The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.

Key Points: 
  • The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.
  • It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a non-cancer indication, opening the way for a broader use of PENTIXAFOR outside of oncology.
  • To investigate the potential of PENTIXAFOR the CHUV will recruit, on its own account, up to 60 patients in a so-called investigator initiated study (ISS).
  • PENTIXAFOR is being developed by Eckert & Ziegler’s subsidiary Pentixapharm GmbH primarily as a superiorly sensitive diagnostic for rare blood cancers, among them myelomas, lymphoma and leukaemia.

ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology; Company also Wins First Place in 2022 Brain-Computer Interface Awards

Retrieved on: 
Monday, November 21, 2022
Medical Devices, Health, Other Health, Research, Science, Biotechnology, University of California, San Francisco, EUR, CHUV, Euronext, Partnership, Materials Research Science and Engineering Centers, In the First Place, International, SCI, Interface (computing), Stanford University, Swiss Federal Institute of Aquatic Science and Technology, Loss of Sensation, Science, EIC, Quality of life, Spinal cord injury, Hyperreflexia, U.S. FDA, Pathfinder, EPFL, Swiss Federal Institute of Technology, Research, Spinal cord, Paralysis, Nature, Incontinence, Paraplegia, ARC, Record, European Innovation Council, Tetraplegia, Lausanne University Hospital, University, BCI, Movement, Infection, Hope, Health, NEMO, Brain–computer interface, Medical device, Pharmaceutical industry

Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .

Key Points: 
  • Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .
  • The award was granted to ONWARD and several research partners for their submission, Walking naturally after spinal cord injury using a brain-spine interface.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis

Retrieved on: 
Thursday, November 10, 2022
Health, Medical Devices, Neurology, Health Technology, Research, Science, Biotechnology, Quality of life, ARC, Forward-looking statement, Health, Partnership, Research, CHUV, Technology, Swiss Federal Institute of Technology, Spinal cord, Neuron, Science, Leg, Spinal cord injury, Lausanne University Hospital, Muscle, SCI, Movement, Company, Program, Walking, Materials Research Science and Engineering Centers, Euronext, Hyperreflexia, EPFL, CEO, U.S. FDA, Swiss Federal Institute of Aquatic Science and Technology, Paralysis, Medical device, Trapping, Nature

The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.

Key Points: 
  • The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Reports Third Quarter 2022 Highlights and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
Medical Devices, Health, FDA, Research, Science, Biotechnology, ARC, Company, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health, Spinal cord, EUR, Quality of life, U.S. FDA, Government, Director, CHUV, Swiss Federal Institute of Aquatic Science and Technology, Arm, Forward-looking statement, Partnership, SIX Financial Information, Webcast, Lausanne University Hospital, FDA, Nature, Public, EPFL, McKinsey & Company, Science, Spinal cord injury, Safety, Technology, CEO, SCI, Food, Movement, Diagnosis, Physician, Swiss Federal Institute of Technology, CET, Patient, Board, Neurogenic bladder dysfunction, Euronext, NIH, Investment, Hemiunu, Marketing, Hyperreflexia, Medical device, Pharmaceutical industry, Tutoring, Risk management, EU, Zoom

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today discussed highlights from the third quarter of 2022 and provided a business update.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today discussed highlights from the third quarter of 2022 and provided a business update.
  • In September 2022, ONWARD reported positive top-line results from its Up-LIFT pivotal study evaluating transcutaneous stimulation with its external ARC Therapy.
  • In October 2022, ONWARD reported topline results from the LIFT Home study, evaluating the safety and feasibility of ARC-EX Therapy when used at home.
  • In September 2022, ONWARD appointed Vivian Riefberg, a highly accomplished expert in healthcare, government, and strategy, to the Board of Directors.

ONWARD Schedules Webcast to Provide Third Quarter Business Update and Announces Participation at Upcoming Conferences

Retrieved on: 
Thursday, October 27, 2022
Software, Finance, Hardware, Health, Medical Devices, Health Technology, Professional Services, Technology, Science, Spinal cord injury, Swiss Federal Institute of Aquatic Science and Technology, CET, Nature, U.S. FDA, Movement, Swiss Federal Institute of Technology, Technology, Quality of life, Company, Partnership, Spinal cord, EPFL, Lausanne University Hospital, ARC, Health, CHUV, Medical device, Risk management

Lara Smith Weber will give a company presentation and be available for questions together with Markus Rieger, Field Clinical Specialist.

Key Points: 
  • Lara Smith Weber will give a company presentation and be available for questions together with Markus Rieger, Field Clinical Specialist.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

World's largest data set of 40m data points offers tremendous potential for cuffless devices to revolutionize the model of care for hypertension

Retrieved on: 
Friday, June 17, 2022
Data, Time, Imperial College London, Industry, BP, Map, Technology, Workflow, Nephrology, Research, IIA, Patient, CHUV, Diagnosis, Collection, Lausanne University Hospital, Service, Pharmaceutical industry, Medical device, Hypertension

NEUCHATEL, Switzerland, June 17, 2022 /PRNewswire/ -- Tomorrow, Aktiia hosts breakout symposium at the 31st European Meeting on Hypertension and Cardiovascular Protection in Athens to share research, data and unite leading experts in hypertension in the mission to improve blood pressure control for 100 million people over the next 10 years.

Key Points: 
  • Aktiia's wrist-based continual optical BP monitor has enabled collection of over 40 milliondata points, establishing the largest dataset of BP readings in the world and demonstrating the huge potential for cuffless devices to unlock new insights.
  • Even with the most comprehensive BP database in the world, treatment and management of hypertension remains a persistent clinical challenge.
  • Aktiia's wrist-worn 24/7 automated blood pressure monitor removes the hassle, discomfort, and disruption of having to take a measurement with a cuff.
  • Aktiiahas CE Mark class IIa medical device approval, and to date over 40 million measurements have been taken across Europe.

World's largest data set of 40m data points offers tremendous potential for cuffless devices to revolutionize the model of care for hypertension

Retrieved on: 
Friday, June 17, 2022
Data, Time, Imperial College London, Industry, BP, Map, Technology, Workflow, Nephrology, Research, IIA, Patient, CHUV, Diagnosis, Collection, Lausanne University Hospital, Service, Pharmaceutical industry, Medical device, Hypertension

NEUCHATEL, Switzerland, June 17, 2022 /PRNewswire/ -- Tomorrow, Aktiia hosts breakout symposium at the 31st European Meeting on Hypertension and Cardiovascular Protection in Athens to share research, data and unite leading experts in hypertension in the mission to improve blood pressure control for 100 million people over the next 10 years.

Key Points: 
  • Aktiia's wrist-based continual optical BP monitor has enabled collection of over 40 milliondata points, establishing the largest dataset of BP readings in the world and demonstrating the huge potential for cuffless devices to unlock new insights.
  • Even with the most comprehensive BP database in the world, treatment and management of hypertension remains a persistent clinical challenge.
  • Aktiia's wrist-worn 24/7 automated blood pressure monitor removes the hassle, discomfort, and disruption of having to take a measurement with a cuff.
  • Aktiiahas CE Mark class IIa medical device approval, and to date over 40 million measurements have been taken across Europe.

clinical data show significantly lower iud procedural pain and bleeding rates with aspivix's novel SUCTION-BASED CERVICAL Device

Retrieved on: 
Wednesday, May 25, 2022
Department, Adolescence, Vacuum, Pain, Company, Michel Bernholc, Traction, Comparison, SA, Birth control, Fear, Norwest Venture Partners, Trauma, HUG, ZKB, European Society of Gynaecological Oncology, New Oakland Child-Adolescent and Family Center, Method, Birth, Advancing Women Artists Foundation, Designated terrorist organisations in Australia, Intrauterine device, Bleeding, IUD, Congress, Safety, Reproduction, Lausanne University Hospital, Geneva University Hospitals, CHUV, Atraumatic Restorative Treatment (ART), Framework Programmes for Research and Technological Development, Reproductive health, PMID, Woman

Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.

Key Points: 
  • Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.
  • During IUD insertion, twice as many nulliparouswomenin the Carevix group were free of pain compared to those in the tenaculum group, and they reported an 88% lower rate of severe pain.
  • Carevixis an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed.
  • A semi-circular, anatomical pad is applied onto the delicate tissue during gynecological procedures, reducing trauma associated with pain and bleeding.

CLINICAL DATA SHOW SIGNIFICANTLY LOWER IUD PROCEDURAL PAIN AND BLEEDING RATES WITH ASPIVIX'S NOVEL SUCTION-BASED CERVICAL DEVICE

Retrieved on: 
Wednesday, May 25, 2022
Department, Adolescence, Vacuum, Pain, Company, Michel Bernholc, Traction, Comparison, SA, Birth control, Fear, Norwest Venture Partners, Trauma, HUG, ZKB, European Society of Gynaecological Oncology, New Oakland Child-Adolescent and Family Center, Method, Birth, Designated terrorist organisations in Australia, Advancing Women Artists Foundation, Intrauterine device, Bleeding, IUD, Congress, Safety, Reproduction, Lausanne University Hospital, Geneva University Hospitals, CHUV, Atraumatic Restorative Treatment (ART), Framework Programmes for Research and Technological Development, Reproductive health, PMID, Woman

Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.

Key Points: 
  • Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.
  • During IUD insertion, twice as many nulliparouswomenin the Carevix group were free of pain compared to those in the tenaculum group, and they reported an 88% lower rate of severe pain.
  • Carevixis an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed.
  • A semi-circular, anatomical pad is applied onto the delicate tissue during gynecological procedures, reducing trauma associated with pain and bleeding.

Project for Futuristic Surgical Training Receives CHF 12 Million in Funding

Retrieved on: 
Tuesday, May 17, 2022
Software, Hardware, Data Management, Training, Technology, Medical Devices, Hospitals, Education, Surgery, Science, Biotechnology, Health, Other Science, Zurich University of Applied Sciences, VirtaMed, Surgeon, Doctor of Philosophy, Solution, COVID-19, ETH Zurich, ZHAW, Time, University, Hospital, Lausanne University Hospital, University of Zurich, CHUV, The Canton Hospital, CHF, Curriculum, Aircraft, Applied science, Medicine

Swiss Innovation Agency Innosuisse has awarded a grant of CHF 12 million over the next four years in support of the "PROFICIENCY" project for surgical simulation.

Key Points: 
  • Swiss Innovation Agency Innosuisse has awarded a grant of CHF 12 million over the next four years in support of the "PROFICIENCY" project for surgical simulation.
  • The project initiates a paradigm shift in practical training in surgery: away from primary training in the operating room, towards standardized and proficiency-based surgical training curricula.
  • Thanks to technical advances in virtual and augmented reality, many surgical procedures can already be simulated with lifelike accuracy.
  • The disadvantage of this form of training became obvious during the Covid 19 pandemic: surgical training was largely restricted or not possible at all in most hospitals during this time.